Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation

Adenovirus Clinical Trial

Official title:

Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05664126
• Other study ID #: VSTHCT
• Status: Recruiting
• Phase: Phase 2
• Start date: August 1, 2023
• Est. completion date: December 31, 2027

Study information

• Verified date: March 2024
• Source: St. Jude Children's Research Hospital
• Contact: Naik Swati, MD
• Phone: 866-278-5833
• Email: referralino[@]stjude.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators want to learn if CMV- and ADV-specific T-cells (cells that fight infections) isolated (selected) from a donor using an automated medical device can be a safe treatment for treating patients with CMV, and ADV after transplant.This study will test the effects and safety of giving VSTs produced here at St. Jude in treating the participant's infection.

Primary objective

To determine the efficacy of VSTs to achieve a ≥1 log10 reduction in CMV and/or ADV viral load in the peripheral blood 4 weeks after VST infusion.

When the initial viral load is <1 log10 above the threshold of detection, the objective is to achieve a reduction to below the threshold of detection.

Secondary objectives

• Determine the safety of VSTs when used to treat CMV and/or ADV viremia post-HCT.

• Determine the proportion of patients who achieve a negative viral load at 3 months post-infusion.

• Assess the persistence of response for 6 months post-infusion.

Description:

The study will have 2 cohorts. Cohort A will include haploidentical donor who is identical to the stem cell donor. Cohort B will include haploidentical donor who is different from the stem cell donor. Seropositive donors will be screened for the presence of CMV- and ADV-specific T-cells using a functional flow cytometry assay. The donor will be considered suitable if the percentage of CD3+/IFN-γ+ cells is greater than 0.01% of CD3+ T-cells. Donor leukocytes will be collected using the Spectra Optia system. CMV- and ADV-specific T-cells will be isolated from donor leukocytes by 'IFN-γ-capture' technology using the Prodigy device over a 24-36 hour period and infused.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 64
• Est. completion date: December 31, 2027
• Est. primary completion date: December 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 18 Years

Eligibility

Inclusion Criteria:

• Patients who have undergone haploidentical HCT or a matched-sibling/matched-unrelated donor HCT, and have CMV and/or ADV detected by PCR in the peripheral blood refractory to antiviral therapy per institutional BMTCT SOP 20.05.

• Definition of "refractory" viremia is persistent positive CMV or ADV viremia after 14 days of treatment per institutional SOP, or an increasing copy number (=1 log) after 7 days of treatment.

• Patients have no suspected or confirmed GVHD.

• Availability of haploidentical donor for isolation of virus-specific T-cells.

• Have not received a Donor Lymphocyte Infusion in the past 4 weeks.

• Female patients of childbearing age must have a negative pregnancy test.

• Subject, parent, or guardian are capable of giving signed informed consent.

• Patients must have a shortening fraction >26% or left ventricular ejection fraction >40%.

• Patients must have a bilirubin less than or equal to 2.5mg/dL and alanine aminotransferase (ALT) less than or equal to 5 times the upper limit of normal.

• Patients must have an estimated glomerular filtration rate (GFR) greater than 60mL/min/1.73m2.

• Patients must be free of severe infection which upon determination of the principal investigator precludes therapy with VST.

• Patients must have FVC >50% predicted or if unable to perform pulmonary function testing must maintain pulse oximetry saturation > 92% on room air.

• Patients must have engrafted with an ANC >500 cells/mm3 for 3 consecutive days.

Inclusion criteria for donors

• Age =18 years.

• At least single haplotype matched (=3/6) family member.

• Donor will be identical to the stem cell donor (Cohort A) or different from the stem cell donor (Cohort B).

• HIV negative.

• For females of childbearing age: Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment AND not lactating with intent to breastfeed.

• Regarding donation eligibility, is identified as either having completed the process of donor eligibility determination as outlined in 21CFR 1271 and agency guidance or does not meet 21CFR 1271 eligibility requirements but has a declaration of urgent medical need completed by the principal investigator or physician sub-investigator per 21CFR.

• Identified recipient with CMV and/or ADV reactivation post-HCT.

Exclusion Criteria:

• Active GVHD.

• Pregnancy.

• Inability to provide consent.

• Need for vasopressor or ventilatory support Patients receiving steroids >0.5 mg/kg prednisone equivalent at the time of VST infusion

• Donor Lymphocyte Infusion within 4 weeks prior to VST infusion.

• Receipt of Thymoglobulin or Alemtuzumab within 30 days of VST infusion.

Related Conditions & MeSH terms

• Adenoviridae Infections
• Adenovirus
• Cytomegalovirus

Intervention

Drug:
• VST infusion
single intravenous (IV) infusion.

Device:
• CliniMACS
Cells infusions are prepared using the ClinMACS

Locations

Country	Name	City	State
United States	St . Jude Children's Research Hospital	Memphis	Tennessee

Sponsors (1)

Lead Sponsor	Collaborator
St. Jude Children's Research Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Degree of reduction of CMV and/or ADV viral load	The primary objective of this clinical study is to evaluate the efficacy of adoptively transferred CMV- and ADV-specific haploidentical T-cells in patients who have undergone allogeneic HCT. This primary endpoint is defined as =1 log10 reduction in CMV and/or ADV viral load 4 weeks after VST infusion. When the initial viral load is <1 log10 above the threshold of detection the endpoint will be a reduction to below the threshold of detection. The success rate will be evaluated using descriptive statistics (sample proportion and standard error). Patients with both CMV and ADC detected will count as success if reduction occurs in one or both of CMV and ADV.	4 weeks after VST infusion
Secondary	Incidence of infusion-related grade 3-5 adverse events 24 hours after infusion	The incidence of infusion-related grade 3-5 adverse events will be estimated using descriptive statistics (sample proportions and cumulative incidence curves with standard errors)	24 hours after infusion
Secondary	Incidence of AEs related to grade 3-4 cytokine release syndrome (CRS), or grade 1-2 CRS persist beyond 72 hours despite therapy	The incidence of AEs related to grade 3-4 cytokine release syndrome (CRS), or grade 1-2 CRS persist beyond 72 hours despite therapy will be estimated using descriptive statistics (sample proportions and cumulative incidence curves with standard errors)	4 weeks after VST infusion
Secondary	Incidence of Grade 3-4 Neurotoxicity of any duration	The incidence of Grade 3-4 Neurotoxicity of any duration will be estimated using descriptive statistics (sample proportions and cumulative incidence curves with standard errors)	4 weeks after VST infusion
Secondary	Incidence of Grade 3-4 GVHD	The incidence of Grade 3-4 GVHD will be estimated using descriptive statistics (sample proportions and cumulative incidence curves with standard errors)	4 weeks after VST infusion
Secondary	Incidence of grade 3-5 non hematologic toxicities attributable to VST	The incidence of grade 3-5 non hematologic toxicities attributable to VST will be estimated using descriptive statistics (sample proportions and cumulative incidence curves with standard errors)	4 weeks after VST infusion
Secondary	Incidence of secondary graft failure attributable to VST	The incidence of secondary graft failure attributable to VST will be estimated using descriptive statistics (sample proportions and cumulative incidence curves with standard errors)	4 weeks after VST infusion
Secondary	Proportion of patients who achieve a negative viral load result at 3 months	The proportion of patients who achieve a negative viral load result at 3 months will be assessed using descriptive statistics (sample proportions with standard errors)	3 months after VST infusion
Secondary	Persistence of response at 6 months post-infusion	The persistence of response at 6 months post-infusion will be assessed using descriptive statistics (sample proportions with standard errors)	6 months after VST infusion

External Links

•   Clinical Trials Open at St.Jude
•   St. Jude Children's Research Hospital